Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Date:3/8/2011

fied from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.KERYX CONTACT:

Lauren Fischer

Director – Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.comKeryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):Three Months Ended December 31, Year Ended December 31,2010200920102009REVENUE:License revenue

$
--

$
--

$
--

$
21,616Service revenue

--

--

--

3Other revenue

--

--

--

3,575TOTAL REVENUE--

--

--

25,194OPERATING EXPENSES:Research and development:Non-cash compensation

238

283

1,236

1,233Other research and development

4,144

3,015

13,728

7,372Total research and development

4,382

3,298

14,964

8,605General and administrative:Non-cash compensation

278

219

1,237

1,867Other general and administrative

1,341

1,431

5,014

4,904Total general and administrative

1,619

1,650

6,251

6,771TOTAL OPERATING EXPENSES6,001

4,948

21,215

15,376OPERATING (LOSS) INCOME(6,001)

(4,948)

(21,215)

9,818OTHER INCOME: Interest a
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
2. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently ... need to urgently address this issue has been emphasized by ... , "Medical device alarm safety in hospitals." According to The ... June 2012, there were 98 alarm related events reported, of ... , 13 resulted in permanent loss of function (13%) ...
(Date:6/19/2013)... Calif. , June 19, 2013  Finesse ... solutions for life sciences process applications, announced the ... bioreactors for upstream cell culture and fermentation.  The ... new product family of Finesse bioreactors and are ... cGMP applications.  They are fully compatible with all ...
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... June 18 Watson Pharmaceuticals, Inc. (NYSE: ... Watson management will provide an overview and update of the ... on Wednesday, June 23, 2010 at 11:15am ... . The presentation will be webcast live and can be ...
... , RESEARCH TRIANGLE PARK, N.C. , June 18 ... of Talecris Biotherapeutics (Nasdaq: TLCR ), received the Ernst ... health sciences category in the Carolinas at a ceremony last ... awards program recognizes entrepreneurs who demonstrate extraordinary success in the ...
Cached Medicine Technology:Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference 2Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients 2
(Date:6/19/2013)... (PRWEB) June 19, 2013 Kansas City will host ... Main Street Day . A section of Main Street in ... during the afternoon of the event. The Main Street Corridor ... event, which will help Kansas City join the ranks of dozens ... as a tool to foster community vibrancy and active lifestyles. , ...
(Date:6/19/2013)... June 19, 2013 Amerinet, Inc, ... ARAMARK Healthcare Technologies to help Pacific Medical Centers ... savings of more than 17 percent over the ... expenditures. , “Driving economies of scale and process ... management challenges facing multi-site providers,” said Shawn Padilla, ...
(Date:6/19/2013)... New data, published today in Menopause International ... experiencing less sex, and less satisfying sex compared ... they are considerably less likely to access appropriate ... atrophy1. , The first-of-its-kind study, called the CLarifying ... study, showed that British post-menopausal women with vaginal ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... , a premier kids entertainment media organization, and ... serious games company, will be introducing the Games ... StudenTopia. The 3D game is geared toward students ... eating and active lifestyles by rewarding positive choices. ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:British women 50 percent less likley to recieve treatment for common menopausal symptoms 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, is honored to receive the eHealthcare,Leadership ... the,Consumer/Disease-Focused category. DaVita.com was one of 1,100 entries,submitted ... program,recognizes websites in the healthcare industry such as ...
... BRIDGEWATER, N.J., Dec. 8 R&J Public Relations, a ... retained to engage in public relations initiatives to promote ... MAQUET is a leading global provider of medical ... technologies. , , ...
... Water is a critical ingredient in the manufacturing process ... quality water (HQW) is the single biggest driver for ... in the pharmaceutical sector. Frost & Sullivan,s European Environment ... wastewater management market in the European pharmaceutical industry has ...
... Cleveland Clinic,s Department of Orthopaedic Surgery, available for download as a PDF, ... ... (PRWEB) December 8, 2008 -- In 2008, 240,000 people in the United ... not inevitable. A new guide from Cleveland Clinic includes a multitude ...
... has joined the staff at the St. John-Clark Pain ... St. John, Randall Clark, Tracy Alan Jones, Brunella Lucchi ... rest of the clinic,s dream team. From chicago, ... recruiting top therapists from across the country who specialize ...
... , ... West Chester, PA (PRWEB) December 5, 2008-- ... of its Precious Metal tubing production capacity due to increasing demand ... metals - Platinum, in particular - are characterized by a high ...
Cached Medicine News:Health News:DaVita.com Receives eHealthcare Leadership Award 2Health News:R&J Public Relations Selected to Promote MAQUET Inc.'s VARIOP Operating Room Suite in North America 2Health News:Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe 2Health News:Cleveland Clinic Issues New Guide for Chronic Hip Pain 2Health News:Cleveland Clinic Issues New Guide for Chronic Hip Pain 3Health News:The St. John-Clark Pain Treatment Center Forms Manual Therapy 'Dream Team' 2Health News:Johnson Matthey Medical Announces Expansion 2
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: